Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cytogfr.2020.06.012 http://scihub22266oqcxt.onion/10.1016/j.cytogfr.2020.06.012 32616381!7313507!32616381     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cytokine+Growth+Factor+Rev 2020 ; 54 (ä): 8-23 Nephropedia Template TP {{tp|p=32616381|t=2020. A critical evaluation of glucocorticoids in the management of severe COVID-19 |pdf=|usr=}}{{32616381}} gab.com Text A critical evaluation of glucocorticoids in the management of severe COVID-19 JO: Cytokine Growth Factor Rev http://www.kidney.de/pget.php?&tw=1&pmid=32616381 #FOAvip The viral infection by SARS-CoV-2 has irrevocably altered the life of the majority of human beings, challenging national health systems worldwide, and pushing researchers to rapidly find adequate preventive and treatment strategies. No therapies have been shown effective with the exception of dexamethasone, a glucocorticoid that was recently proved to be the first life-saving drug in this disease. Remarkably, around 20 % of infected people develop a severe form of COVID-19, giving rise to respiratory and multi-organ failures requiring subintensive and intensive care interventions. This phenomenon is due to an excessive immune response that damages pulmonary alveoli, leading to a cytokine and chemokine storm with systemic effects. Indeed glucocorticoids' role in regulating this immune response is controversial, and they have been used in clinical practice in a variety of countries, even without a previous clear consensus on their evidence-based benefit. Twit Text FOAVip A critical evaluation of glucocorticoids in the management of severe COVID-19 ????Cytokine Growth Factor Rev http://www.kidney.de/pget.php?&tw=1&pmid=32616381 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32616381 #FOAvip English Wikipedia <ref>{{Cite pmid|32616381}}</ref> A critical evaluation of glucocorticoids in the management of severe COVID-19 #MMPMID32616381 Solinas C; Perra L; Aiello M; Migliori E; Petrosillo N Cytokine Growth Factor Rev 2020[Aug]; 54 (ä): 8-23 PMID32616381show ga The viral infection by SARS-CoV-2 has irrevocably altered the life of the majority of human beings, challenging national health systems worldwide, and pushing researchers to rapidly find adequate preventive and treatment strategies. No therapies have been shown effective with the exception of dexamethasone, a glucocorticoid that was recently proved to be the first life-saving drug in this disease. Remarkably, around 20 % of infected people develop a severe form of COVID-19, giving rise to respiratory and multi-organ failures requiring subintensive and intensive care interventions. This phenomenon is due to an excessive immune response that damages pulmonary alveoli, leading to a cytokine and chemokine storm with systemic effects. Indeed glucocorticoids' role in regulating this immune response is controversial, and they have been used in clinical practice in a variety of countries, even without a previous clear consensus on their evidence-based benefit. |Anti-Inflammatory Agents/*therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |Betacoronavirus/drug effects[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/pathology[MESH] |Cytokine Release Syndrome/*drug therapy[MESH] |Dexamethasone/*therapeutic use[MESH] |Glucocorticoids/*therapeutic use[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/pathology[MESH] |Pulmonary Alveoli/pathology[MESH]A critical evaluation of glucocorticoids in the management of severe C(epmc).pdf DeepDyve Pubget Overpricing